https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43675 P = 0.005), whereas there was no such association between reperfusion and an excellent outcome with any of the CCM criteria (all p > 0.05). Notably, in IVT-LVO cohort, 58.2% of the PIM-DT positive patients achieved an excellent outcome compared with 31.0% in non-mismatch patients following successful recanalization (P = 0.006).]]> Wed 28 Sep 2022 14:35:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51451 3 seconds on CTP. Regression analyses were used to identify clinical and imaging variables that predicted poor functional outcome. Results: A total of 139 patients with mild stroke were included, of whom 27 (19%) had poor functional outcome. Patients with poor outcome, compared with those with good outcome, had much larger perfusion lesion volume (median 80 mL vs 41 mL, p < 0.001). Perfusion lesion was a significant predictor of poor outcome in either univariable regression (crude OR = 1.02, 95% CI = [1.01-1.03]) or multivariable regression model (adjusted OR = 1.01, 95% CI = [1.01-1.02]), adjusting for occlusion site, good collaterals, baseline stroke severity, age, IV thrombolysis (IVT), and onset to scan time. A perfusion lesion of 65 mL was the optimal cutpoint to identify poor functional outcome (sensitivity = 59%, specificity = 77%). Patients with perfusion lesion ≥65 mL, compared with patients with perfusion lesion <65 mL, showed a much higher rate of poor functional outcome (38% vs 11%, p < 0.001). Of the 139 patients in this study, 95 received IVT. Patients treated with or without IVT did not influence their outcomes (crude OR = 0.74, 95% CI = [0.31-1.78]). Discussion: A perfusion lesion of ≥65 mL predicted poor functional outcome in mild stroke patients with LVO.]]> Wed 28 Feb 2024 15:56:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17648 Wed 11 Apr 2018 16:57:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15711 Wed 05 Dec 2018 17:46:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53281 Tue 21 Nov 2023 10:18:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38979 4.5 h time window between patient groups who met and did not meet the perfusion imaging trial criteria. Methods: A discrete event simulation (DES) model was developed to simulate the long-term outcome post EVT in patients meeting or not meeting the extended time window clinical trial perfusion imaging criteria at presentation, vs. medical treatment alone (including intravenous thrombolysis). The effectiveness of thrombectomy in patients meeting the landmark trial criteria (DEFUSE 3 and DAWN) was derived from a prospective cohort study of Australian patients who received EVT for ischemic stroke, between 2015 and 2019, in the extended time window (>4.5 h). Results: Endovascular thrombectomy was shown to be a cost-effective treatment for patients satisfying the clinical trial criteria in our prospective cohort [incremental cost-effectiveness ratio (ICER) of $11,608/quality-adjusted life year (QALY) for DEFUSE 3-postive or $34,416/QALY for DAWN-positive]. However, offering EVT to patients outside of clinical trial criteria was associated with reduced benefit (−1.02 QALY for DEFUSE 3; −1.43 QALY for DAWN) and higher long-term patient costs ($8,955 for DEFUSE 3; $9,271 for DAWN), thereby making it unlikely to be cost-effective in Australia. Conclusions: Treating patients not meeting the DAWN or DEFUSE 3 clinical trial criteria in the extended time window for EVT was associated with less gain in QALYs and higher cost. Caution should be exercised when considering this procedure for patients not satisfying the trial perfusion imaging criteria for EVT.]]> Thu 24 Mar 2022 08:55:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21417 Sat 24 Mar 2018 08:05:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20486 Sat 24 Mar 2018 07:59:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30365 Sat 24 Mar 2018 07:26:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26733 Sat 24 Mar 2018 07:26:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22312 Sat 24 Mar 2018 07:14:42 AEDT ]]>